Latigo's lead candidate LTG-001 is in a Phase 2 clinical trial for acute pain relief, with results expected later this year. The company has raised a total of $285 million across its Series A and B funding rounds.
Company Description
Latigo Biotherapeutics is a private drug company developing experimental non-opioid pain medicines targeting the NaV1.8 ion channel in peripheral nerve cells. The company aims to provide pain relief without the addictive risks associated with opioids.
Market
Pain Management
Location
USA
Coinvestors
Blue Owl Capital, 5AM Ventures, Foresite Capital, Alexandria Venture Investments, Westlake Village BioPartners